Targeting key drivers in SCLC for the development of new therapeutic concepts (A07*)

点击翻译按钮获取中文摘要

S. Knapp and his team will continue to work on providing chemical probes to interrogate critical pathways of SCLC tumorigenesis. In particular, they will make their growing collections of chemical probes targeting epigenetic modifiers and kinases for mechanistic studies in SCLC available. Furthermore, they will continue their analysis of chemical-based screening of SCLC cell lines to identify such vulnerabilities. In a new effort to interfere with critical pathways in SCLC, they will strive to create novel molecules to inhibit the catalytic activity of telomerase in a structure-based drug design approach exploiting novel insights from crystallography and EM studies of human telomerase. Finally, the team will continue their efforts on developing chemical degraders for targeted degradation of key proteins involved in SCLC biology including lysine methyl transferases such as G9A in collaboration with Michael Hölzel's group.